Enhancement of antitumor activity of the oxazaphosphorine cytostatic SUM-IAP by N-methylformamide
- 107 Downloads
SUM-IAP has been developed with the aim to optimize therapeutic response and minimize toxic reactions of oxazaphosphorine cytostatics. In therapy tests in mice, the primary tumor was successfully eradicated, but animals died due to formation of lethal metastases. We supposed that high activities of SUM-IAP detoxifying enzymes caused metastasis formation in the liver. Therefore, therapy tests with SUM-IAP in combination with cisplatin and N-methylformamide (NMF), which were not detoxified in the liver, were carried out.
Antitumor activity was assayed in female CD2F1 mice with advanced subcutaneously growing P388 mice leukemia cells.
The results of the therapy tests with SUM-IAP plus cisplatin were as expected: No formation of metastases and long-time survival of more than 100 days were observed; however, the toxicity was increased as measured by decrease in body weight and the number in leukocytes. The results of the tests in combination with NMF were surprising: Applying only half the dose of SUM-IAP used in the experiments with cisplatin, no metastases were found and long-time survivors did not show signs of additional toxicity.
NMF strongly enhances the antitumor activity of the oxazaphosphorine cytostatic SUM-IAP in mice with subcutaneously growing P388 mice leukemia cells by an unknown mechanism of action.
KeywordsOxazaphosphorine cytostatics SUM-IAP N-methylformamide Cisplatin
For critical review and proof reading of the manuscript, I thank Prof. Frank Nürnberger and Prof. Stefan Müller Goethe University Frankfurt, Medical School, Frankfurt am Main, Germany.
This study was funded by the Bundesministerium für Forschung und Technologie.
Compliance with ethical standards
Conflict of interest
The author declares no conflict of interest.
All applicable international, national and institutional guidelines for the care and use of animals were followed.
- Codeiro RF, Savarese TM (1986) Role of glutathione depletion in the mechanism of action of N-methylforamide and N, N-dimethylformamide in a cultured human colon carcinoma cell line. Cancer Res 46:1297–1305Google Scholar
- Hohorst HJ, Bielicki L, Mülller K, Voelcker G (1988) Low toxicity cancer chemotherapy by suicide inactivation of DANN polymerase holoenzyme: first results with new thiazolidinyl- and perhydrothiazinyl-ethyl-N-mustard-phosphamide-esters. J Cancer Res Clin Oncol 114:309–311CrossRefPubMedGoogle Scholar
- Voelcker G, Bielicki L, Hohorst HJ (1981) Evidence for enzymatic toxification of activated Cyclophosphamide (4-hydroxycyclophosphamide). J Cancer Res Clin Oncol 99A:58–59Google Scholar